Rajiv Kumar Kaushal

8PUBLICATIONS
33CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Cancer geneticsMedical microbiology not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jan 28, 2026
Efficacy and Safety of Ultra-Low-Dose Immunotherapy in Relapsed Refractory Solid Tumors: Phase III Superiority Randomized Trial (DELII).

Vanita Noronha, Vijay Patil, Nandini Menon

|Sep 16, 2024
Correction: Deep learning based automated epidermal growth factor receptor and anaplastic lymphoma kinase status prediction of brain metastasis in non-small cell lung cancer.

Abhishek Mahajan, Gurukrishna B, Shweta Wadhwa

|Aug 19, 2024
Performance of Low-Dose Immunotherapy and Standard-Dose Immunotherapy in Microsatellite Instability-High Metastatic Colorectal Cancer: Real-World Data (CLouD-High Study).

Mehak Trikha, Laboni Sarkar, Aditya Dhanawat

|Aug 05, 2024
Bevacizumab Erlotinib Switch Maintenance in Chemo-Responsive Advanced Gallbladder and Cholangiocarcinoma (BEER BTC): A Multicenter, Open-Label, Randomized, Phase II Trial.

Anant Ramaswamy, Prabhat Bhargava, Sujay Srinivas

|Nov 09, 2023
Trastuzumab Plus Gemcitabine-Cisplatin for Treatment-Naïve Human Epidermal Growth Factor Receptor 2-Positive Biliary Tract Adenocarcinoma: A Multicenter, Open-Label, Phase II Study (TAB).

Vikas Ostwal, Sarika Mandavkar, Prabhat Bhargava

|Sep 25, 2023
Deep learning based automated epidermal growth factor receptor and anaplastic lymphoma kinase status prediction of brain metastasis in non-small cell lung cancer.

Abhishek Mahajan, Gurukrishna B, Shweta Wadhwa

Pageof 2

Frequent Collaborators

4 joint publications

Vikas Ostwal

4 joint publications

Anant Ramaswamy

4 joint publications

Prabhat Bhargava

3 joint publications

Subhash Yadav